SCHEMBL7046524

SCHEMBL7046524

COc1nn(-c2cccc(NC(=O)Nc3ccccn3)c2)c(=O)o1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 4/20 0.53
NPC1 O15118 5/20 0.50
RAB9A P51151 5/20 0.50
LMNA P02545 3/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
ABHD16A O95870 1/20 0.48
ADORA3 P0DMS8 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
PIM1 P11309 1/20 0.48
ADORA2A P29274 1/20 0.48
ADORA2B P29275 1/20 0.48
ADORA1 P30542 1/20 0.48
FLT3 P36888 1/20 0.48
PIM3 Q86V86 1/20 0.48
AURKB Q96GD4 1/20 0.48
NTRK1 P04629 3/20 0.47
FAAH O00519 2/20 0.46
MAPK13 O15264 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7650640 0.89 LPL (0.56) MGLLNPC1RAB9ALMNACYP2C9
SCHEMBL7657538 0.82 MGLL (0.59) MGLLNPC1RAB9ALMNAABHD16A
SCHEMBL6598671 0.74 MGLL (0.52) MGLLABHD16AFAAHMEN1KMT2A
SCHEMBL7043150 0.73 MGLL (0.63) MGLLABHD16AFAAHLIPCLIPE
SCHEMBL6601500 0.71 ALDH1A1 (0.51) MGLLNPC1RAB9ALMNAABHD16A
SCHEMBL11620781 0.71 FAAH (0.78) MGLLABHD16AFAAHLPLLIPC
SCHEMBL6552790 0.71 MGLL (0.74) MGLLABHD16AFAAHLIPCLIPE
SCHEMBL25403693 0.70 GAA (0.71) NPC1RAB9ALMNACYP1A2CYP2C9
SCHEMBL6551376 0.70 MGLL (1.00) MGLLABHD16AFAAHLIPCLIPE
SCHEMBL7047523 0.69 MGLL (0.67) MGLLABHD16AFAAHLIPCLIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase AVENTIS PHARMA DEUTSCHLAND GMBH 2003-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase PNLIP, CEL, LIPE MGLL 10/4885NPC1 730/4885RAB9A 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.